Corcept Therapeutics Inc CORT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Corcept Resubmits FDA Application for Cushing Syndrome Drug
-
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
-
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
-
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
-
Corcept Plans to Resubmit Cushing's Syndrome Drug Application to FDA
-
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
-
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
-
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Trading Information
- Previous Close Price
- $91.57
- Day Range
- $91.21–95.79
- 52-Week Range
- $28.66–95.79
- Bid/Ask
- $94.69 / $97.90
- Shares Outstanding
- 107.35M
- Market Cap
- $10.27B
- Volume/Avg
- 839,334 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 258.63
- Price/Sales
- 13.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 730
- Website
- https://www.corcept.com
Valuation
|
Metric
|
CORT
|
|---|---|
Price/Earnings (Normalized) | 273.29 |
Price/Book Value | 16.09 |
Price/Sales | 14.44 |
Price/Cash Flow | 118.31 |
Price/Earnings
CORT
Financial Strength
|
Metric
|
CORT
|
|---|---|
Quick Ratio | 2.53 |
Current Ratio | 2.86 |
Interest Coverage | — |
Quick Ratio
CORT
Profitability
|
Metric
|
CORT
|
|---|---|
Return on Assets (Normalized) | 13.95% |
Return on Equity (Normalized) | 17.77% |
Return on Invested Capital (Normalized) | 15.12% |
Return on Assets
CORT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|k>Yfcq | LOCK|$?gT | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|yF^wsk | LOCK|hCd^l | $71B | |||
| argenx SE ADR
ARGX
| LOCK|sHFsSmF | LOCK|lt | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Fw#kKX# | LOCK|tj | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|tDBC@s | LOCK|xl&% | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$s&?&ws | LOCK|>gq&P | $26B | |||
| Moderna Inc
MRNA
| LOCK|!R&!V@> | LOCK|&V | $24B | |||
| Incyte Corp
INCY
| LOCK|<Q!%l^ | LOCK|@j | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|LWF>w#% | LOCK|!zZ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|QG^!%^ | LOCK|R@< | $16B |
United States